Chester County News and Community Website
RADNOR, PA — Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) is set to release its financial results for the second quarter ended June 30, 2024, on August 13, 2024. The company will …
Marinus Pharmaceuticals to Announce Q2 Financial Results Read More RADNOR, PA — Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) has announced that China’s National Medical Products Administration (NMPA) has approved its ganaxolone oral suspension. This drug targets epileptic seizures in patients …
Marinus Pharmaceuticals Gains Approval for Seizure Drug in China Read More RADNOR, PA — Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) recently announced the topline results from its Phase 3 RAISE trial, which evaluated the safety and efficacy of intravenous (IV) ganaxolone in …
Marinus Pharmaceuticals Reports Mixed Results from Phase 3 RAISE Trial for Refractory Status Epilepticus Treatment Read More RADNOR, PA — Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) recently completed enrollment for its global Phase 3 TrustTSC trial, which is evaluating the efficacy of oral ganaxolone in treating seizures associated …
Marinus Pharmaceuticals Completes Enrollment for Phase 3 Trial on Tuberous Sclerosis Complex Read More RADNOR, PA — Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a biopharmaceutical company focused on innovative treatments for seizure disorders, has announced a significant increase in Q1 2024 revenues and provided updates …
Marinus Pharmaceuticals Reports Strong Growth and Advances in Seizure Disorder Treatments Read More RADNOR, PA — Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) announced its participation in the upcoming RBC Capital Markets 2024 Global Healthcare Conference.
Marinus Pharmaceuticals CEO to Speak at RBC Healthcare Conference Read More RADNOR, PA — Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a leader in developing treatments for seizure disorders, will unveil its first-quarter financials for 2024 on May 8, prior to market opening.
Marinus Pharmaceuticals to Announce First Quarter Financial Results Read More RADNOR, PA — Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) recently announced its decision to proceed with the Phase 3 RAISE trial of intravenous (IV) ganaxolone for treating refractory status epilepticus (RSE), …
Marinus Pharmaceuticals Continues Phase 3 Trial for Epilepticus Treatment Despite Setback Read More